CELECOXIB–CHALCONE HYBRIDIZATION GENERATESDUAL COX-2/FACTOR XA INHIBITORS WITHENHANCEDCOX-2 SELECTIVITY: AN In-silico DRUG DESIGN STUDY
Anti-inflammatory selective cyclooxygenase-2 (COX-2) inhibitors have minimal gastrointestinal toxicity comparedwith non-selective NSAIDs; however, cardiovascular concerns associated with selective COX-2 inhibitors highlight the need for safer anti-inflammatory agents. This study aimed to design celecoxib-based chalcone derivatives withenhanced COX-2 selectivity and potential factor Xa inhibitory activity. Fifty derivatives were rationally designedbyintroducing an α,β-unsaturated carbonyl linker between the phenyl and pyrazole rings and subjected to in-silicoevaluation using toxicity, physicochemical, ADME, and molecular docking studies against COX-2, COX-1, andanticoagulant factor (factor Xa). Of the 50 derivatives, 45 showed stronger predicted COX-2 binding than celecoxib, with reduced COX-1 interaction, while several exhibited favourable factor Xa affinity. The study has predictedleadmolecules for the development of safer anti-inflammatory therapeutics with reduced cardiovascular risk. Thus, thepresent work contributes to the advancement of multitarget drug design strategies and supports United NationsSustainable Development Goal (SDG) 3: Good Health and Well-being